Dorval Allison — SEC Form 4 filings
SEC reporting owner CIK 1625110. 11 Form 4 filings on record with FilingPulse; latest filed 2026-06-15.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-02-16 to 2026-06-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings — 38,125 shares, $177,182 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 11,610 shares @ $7.20 ($83,579) in PUMA BIOTECHNOLOGY, INC., filed 2026-06-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | Director | 5 | — | 3 legs · 34,220 sh · $160,150 | 3 |
| Verve Therapeutics, Inc. (VERV) | Chief Financial Officer | 5 | — | 2 legs · 3,905 sh · $17,033 | 16 |
| Aerovate Therapeutics, Inc. (AVTE) | Director | 1 | — | — | 1 |
Form 4 filings — Dorval Allison
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-15 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 · Sale (S): 11,610 @ $7.20 | EDGAR |
| 2025-07-28 | 4 | Verve Therapeutics, Inc. (VERV) | Code (U): 13,280 · Disposition to issuer (D): 258,000 (derivative) · Disposition to issuer (D): 75,000 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 33,750 (derivative) · Disposition to issuer (D): 1,875 (derivative) · +1 more | EDGAR |
| 2025-06-17 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 11,610 @ $3.40 | EDGAR |
| 2025-06-13 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2025-04-03 | 4 | Verve Therapeutics, Inc. (VERV) | Option exercise (M): 11,250 · Sale (S): 3,350 @ $4.15 · Option exercise (M): 11,250 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 258,000 (derivative) @ $0 · Grant/award (A): 45,000 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-12-03 | 4 | Verve Therapeutics, Inc. (VERV) | Option exercise (M): 1,875 · Sale (S): 555 @ $5.64 · Option exercise (M): 1,875 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Grant/award (A): 27,000 @ $0 | EDGAR |
| 2024-06-17 | 4 | PUMA BIOTECHNOLOGY, INC. (PBYI) | Sale (S): 11,000 @ $3.37 | EDGAR |
| 2024-06-07 | 4 | Aerovate Therapeutics, Inc. (AVTE) | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Verve Therapeutics, Inc. (VERV) | Grant/award (A): 180,000 (derivative) @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1625110 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →